Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Peter, Ansell"'
Autor:
Ramesh K. Ramanathan, Louie Naumovski, Daniel Afar, Edward Reilly, Lan Wang, Huibin Yue, Shekman Wong, Monica Motwani, Peter Ansell, Chia-Chi Lin, Chia Jui Yen, Yoon-Koo Kang, Ravi Salgia, Patricia LoRusso, John H. Strickler
Progression-free survival in MET-amplified patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::145067315457d206ba429757f27f4a59
https://doi.org/10.1158/1535-7163.22518675.v1
https://doi.org/10.1158/1535-7163.22518675.v1
Autor:
Ramesh K. Ramanathan, Louie Naumovski, Daniel Afar, Edward Reilly, Lan Wang, Huibin Yue, Shekman Wong, Monica Motwani, Peter Ansell, Chia-Chi Lin, Chia Jui Yen, Yoon-Koo Kang, Ravi Salgia, Patricia LoRusso, John H. Strickler
This first-in-human phase I study evaluated the pharmacokinetics, safety, and preliminary efficacy of telisotuzumab, formerly called ABT-700, an antagonistic antibody directed against c-Met. For dose escalation (3+3 design), 3 to 6 patients with adva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6640b77d2b8eba127728d9cdd567b7c4
https://doi.org/10.1158/1535-7163.c.6542055.v1
https://doi.org/10.1158/1535-7163.c.6542055.v1
Autor:
Ramesh K. Ramanathan, Louie Naumovski, Daniel Afar, Edward Reilly, Lan Wang, Huibin Yue, Shekman Wong, Monica Motwani, Peter Ansell, Chia-Chi Lin, Chia Jui Yen, Yoon-Koo Kang, Ravi Salgia, Patricia LoRusso, John H. Strickler
Additional details for MET-amplified patients with one or more postbaseline tumor assessment (n=9).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::724d29e98782b3d44b4991678c167d4f
https://doi.org/10.1158/1535-7163.22518666
https://doi.org/10.1158/1535-7163.22518666
Autor:
Vera Gorbunova, Vincent Giranda, Mark McKee, Peter Ansell, Hao Xiong, Juliann Dziubinski, Caroline Nickner, Jiang Qian, Qin Qin, Ulrich Keiholz, Ebenezer Kio, Fabrice Barlesi, Sergey Orlov, Laszlo Urban, Erzsebet Juhasz, C. Michael Jones, Martin Reck, Julien Mazieres, Normand Blais, Suresh S. Ramalingam
Purpose: PARP plays an important role in DNA repair. Veliparib, a PARP inhibitor, enhances the efficacy of platinum compounds and has been safely combined with carboplatin and paclitaxel. The primary endpoint of this phase II trial determined whether
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45e7ce0aeb342f5774b9143be1c1edd9
https://doi.org/10.1158/1078-0432.c.6526571.v1
https://doi.org/10.1158/1078-0432.c.6526571.v1
Autor:
Vera Gorbunova, Vincent Giranda, Mark McKee, Peter Ansell, Hao Xiong, Juliann Dziubinski, Caroline Nickner, Jiang Qian, Qin Qin, Ulrich Keiholz, Ebenezer Kio, Fabrice Barlesi, Sergey Orlov, Laszlo Urban, Erzsebet Juhasz, C. Michael Jones, Martin Reck, Julien Mazieres, Normand Blais, Suresh S. Ramalingam
Supplemental Table 1. Demographics and baseline characteristics by histology: squamous cell Supplemental Table 2. Demographics and baseline characteristics by histology: non-squamous cell Supplemental Table 3. Mean {plus minus} SD pharmacokinetic par
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62499efaffeb259872b1608c05230ee5
https://doi.org/10.1158/1078-0432.22467197
https://doi.org/10.1158/1078-0432.22467197
Autor:
Louis B. Nabors, David A. Reardon, John Simes, Lisa Roberts-Rapp, Ho-Jin Lee, Nicholas Butowski, Tobias Walbert, Andrew B. Lassman, Helen Wheeler, Priya Kumthekar, Andrew M. Scott, Peter Ansell, Tom Mikkelsen, Marta Penas-Prado, Kyriakos P. Papadopoulos, Martin J. van den Bent, Earle Bain, Zarnie Lwin, Erica Gomez, David Maag, Ryan Merrell, Hui K Gan, Hao Xiong, Kyle D. Holen
Publikováno v:
Cancer Chemotherapy & Pharmacology, 80(6), 1209-1217. Springer-Verlag
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Purpose Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, is an antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff65c6833473b7cdb380bda35882ca5
Autor:
Benedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, Andrew B Lassman, Saiama N Waqar, Young Kwang Chae, Jyoti D Patel, Einat Shacham-Shmueli, Karen Kelly, Mustafa Khasraw, Christine M Bestvina, Ryan Merrell, Kevin Huang, Harisha Atluri, Peter Ansell, Rachel Li, Janet Jin, Mark G Anderson, Edward B Reilly, Gladys Morrison-Thiele, Kalpesh Patel, Randy R Robinson, Martha R Neagu Aristide, Hui K Gan
Publikováno v:
Neuro-Oncology Advances. 5
BackgroundSerclutamab talirine (Ser-T, formerly ABBV-321) is an antibody-drug conjugate consisting of an antibody (AM-1-ABT-806) directed against activated epidermal growth factor receptor (EGFR) and a pyrrolobenzodiazepine dimer. We investigated Ser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e850d9c26406dd539e85933a90d92b97
https://doi.org/10.1093/noajnl/vdac183
https://doi.org/10.1093/noajnl/vdac183
Autor:
D. Ross Camidge, Jonathan Goldman, Athan Vasilopoulos, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine Ratajczak, Elysa Noon, Shun Lu
Publikováno v:
Cancer Research. 83:CT214-CT214
Background: Teliso-V is a first-in-class c-Met-directed antibody-drug conjugate comprising the monoclonal antibody telisotuzumab, a cleavable valine-citrulline linker, and the potent microtubule polymerization inhibitor monomethyl auristatin E. In a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf9aad972f902af371105e815f68534c
https://doi.org/10.1158/1538-7445.am2023-ct214
https://doi.org/10.1158/1538-7445.am2023-ct214
Autor:
Cyril Ramathal, David Masica, Peter Ansell, Bridget Riley-Gillis, Jacob Degner, Thanh Bui, Priya Narayanan, Josue Samayoa, Xin Huang, Robert F. Coleman, Jeffrey F. Waring
Publikováno v:
Cancer Research. 83:5426-5426
Discovery and validation of biomarkers derived from multi-dimensional clinico-genomic datasets have become critical in precision medicine and oncology drug development. The integration of multi-dimensional genomic and imaging datasets from patients i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10dbb2081e7f81e1e0aac8c98ff89320
https://doi.org/10.1158/1538-7445.am2023-5426
https://doi.org/10.1158/1538-7445.am2023-5426
Autor:
Hugh D. Falls, Michael J. Mitten, Edward B. Reilly, Adelyn L Zelaya-Lazo, Erwin R. Boghaert, Anatol Oleksijew, Kedar S. Vaidya, Joann P. Palma, Sasmita Mishra, Cory Alvey, Peter Ansell, Mark Anderson, Andrew C. Phillips
Publikováno v:
Journal of Neuro-Oncology. 152:233-243
Purpose: Depatux-m is an antibody drug conjugate (ADC) that targets and inhibits growth of cancer cells overexpressing the epidermal growth factor receptor (EGFR) or the 2–7 deletion mutant (EGFRvIII) in tumor models in vitro and in vivo. Treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da8fe6125027bf7b8125a6d51e3f4e5d
https://doi.org/10.1007/s11060-021-03703-z
https://doi.org/10.1007/s11060-021-03703-z